In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Hosted on MSN4d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...
William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback